Dataset Information

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.

ABSTRACT:

Translational relevance

No prophylactic treatments for COVID-19 have been clearly proven and found. In this pandemic context, cancer patients constitute a particularly fragile population that would benefit the best from such treatments, a present unmet need. TMPRSS2 is essential for COVID-19 replication cycle and it is under androgen control. Estrogen and androgen receptor dependent cues converge on TMPRSS2 regulation through different mechanisms of action that can be blocked by the use of hormonal therapies. We believe that there is enough body of evidence to foresee a prophylactic use of hormonal therapies against COVID-19 and this hypothesis can be easily tested on cohorts of breast and prostate cancer patients who follow those regimens. In case of pandemic, if the protective effect of hormonal therapies will be proven on cancer patients, the use of specific hormonal therapies could be extended to other oncological groups and to healthy individuals to decrease the overall risk of infection by SARS-CoV-2.Given the COVID-19 coronavirus emergency, a special focus is needed on the impact of this rapidly spreading viral infection on cancer patients. Androgen receptor (AR) signaling in the transmembrane protease serine 2 (TMPRSS2) regulation is emerging as an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility. In our study, we analyzed AR and TMPRSS2 expression in 17,352 normal and 9,556 cancer tissues from public repositories and stratified data according to sex and age. The emerging picture is that some patient groups may be particularly susceptible to SARS-CoV-2 infection and may benefit from antiandrogen- or tamoxifen-based therapies. These findings are relevant to choose proper treatments in order to protect cancer patients from concomitant SARS-CoV-2 contagion and related symptoms and put forward the idea that hormonal therapies could be used as prophylactic agents against COVID-19.

SUBMITTER: Bravaccini S

PROVIDER: S-EPMC7863556 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.

Bravaccini Sara S Fonzi Eugenio E Tebaldi Michela M Angeli Davide D Martinelli Giovanni G Nicolini Fabio F Parrella Paola P Mazza Massimiliano M

Cell transplantation 20210101

<h4>Translational relevance</h4>No prophylactic treatments for COVID-19 have been clearly proven and found. In this pandemic context, cancer patients constitute a particularly fragile population that would benefit the best from such treatments, a present unmet need. TMPRSS2 is essential for COVID-19 replication cycle and it is under androgen control. Estrogen and androgen receptor dependent cues converge on TMPRSS2 regulation through different mechanisms of action that can be blocked by the use ...[more]

PMID: 33522308

Similar Datasets

Project description:Background: In December 2019, the novel Coronavirus disease (COVID-19) broke out in Wuhan, China leading to major national and international disruptions in healthcare, business, education, transportation, and nearly every aspect of our daily lives. Artificial Intelligence (AI) has been leveraged amid the COVID-19 pandemic, however, little is known about its use for supporting public health efforts.Objective: The scoping review aimed to explore how AI technology is being used during the COVID-19 pandemic, as reported in the literature. Thus, it is first review that describes and summarizes features of the identified AI techniques and datasets used for their development and validation.Methods: A scoping review was conducted following the guidelines of PRISMA Extension for Scoping Reviews (PRISMA-ScR). We searched the most commonly used electronic databases (e.g., MEDLINE, EMBASE, PsycInfo) between April 10 and 12, 2020. These terms were selected based on the target intervention (i.e., AI) and the target disease (i.e., COVID-19). Two reviewers independently conducted study selection and data extraction. A narrative approach was used to synthesize the extracted data.Results: We considered 82 studies out of the 435 retrieved studies. The most common use of AI was diagnosing COVID-19 cases based on various indicators. AI was also employed in drug and vaccine discovery or repurposing, and assessing their safety. Further, the included studies used AI for forecasting the epidemic development of COVID-19 and predicting its potential hosts/reservoirs. Researchers utilized AI for patient outcome-related tasks such as assessing the severity of COVID-19, predicting mortality risk, its associated factors, and length of hospital stay. AI was used for Infodemiology to raise awareness to use water, sanitation, and hygiene. The most prominent AI techniques used were Convolutional Neural Network (CNN) followed by Support Vector Machine (SVM).Conclusions: The included studies showed that AI has the potential to fight against COVID-19. However, many of the proposed methods are not yet clinically accepted. Thus, the most rewarding research will be on methods promising value beyond COVID-19. More efforts are needed for developing standardized reporting protocols or guidelines for studies on AI.

Project description:In December 2019, when the whole world is waiting for Christmas and New Year, the physicians of Wuhan, China, are astounded by clusters of patients suffering from pneumonia from unknown causes. The pathogen isolated from the respiratory epithelium of the patients is similar to previously known coronaviruses with some distinct features. The disease was initially called nCoV-2019 or SARS-nCoV-2 and later termed as COVID-19 by WHO. The infection is rapidly propagating from the day of emergence, spread throughout the globe and now became a pandemic which challenged the competencies of developed nations in terms of health care management. As per WHO report, 216 countries are affected with SARS-CoV-19 by August 5, 2020 with 18, 142, 718 confirmed cases and 691,013 deaths reports. Such huge mortality and morbidity rates are truly threatening and calls for some aggressive and effective measures to slow down the disease transmission. The scientists are constantly engaged in finding a potential solution to diagnose and treat the pandemic. Various FDA approved drugs with the previous history of antiviral potency are repurposed for COVID-19 treatment. Different drugs and vaccines are under clinical trials and some rapid and effective diagnostic tools are also under development. In this review, we have highlighted the current epidemiology through infographics, disease transmission and progression, clinical features and diagnosis and possible therapeutic approaches for COVID-19. The article mainly focused on the development and possible application of various FDA approved drugs, including chloroquine, remdesivir, favipiravir, nefamostate mesylate, penciclovir, nitazoxanide, ribavirin etc., vaccines under development and various registered clinical trials exploring different therapeutic measures for the treatment of COVID-19. This information will definitely help the researchers to understand the in-line scientific progress by various clinical agencies and regulatory bodies against COVID-19.

Dataset Information

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.

Translational relevance

Publications

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets